IL142588A0 - Therapy for improving cognition - Google Patents

Therapy for improving cognition

Info

Publication number
IL142588A0
IL142588A0 IL14258899A IL14258899A IL142588A0 IL 142588 A0 IL142588 A0 IL 142588A0 IL 14258899 A IL14258899 A IL 14258899A IL 14258899 A IL14258899 A IL 14258899A IL 142588 A0 IL142588 A0 IL 142588A0
Authority
IL
Israel
Prior art keywords
therapy
improving cognition
cognition
improving
Prior art date
Application number
IL14258899A
Other languages
English (en)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of IL142588A0 publication Critical patent/IL142588A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
IL14258899A 1998-10-16 1999-10-12 Therapy for improving cognition IL142588A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98203454 1998-10-16
PCT/EP1999/007804 WO2000023057A2 (en) 1998-10-16 1999-10-12 Atypical antiphsychotic in combination with acetylcholinesterase inhibitor for improving cognition

Publications (1)

Publication Number Publication Date
IL142588A0 true IL142588A0 (en) 2002-03-10

Family

ID=8234219

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14258899A IL142588A0 (en) 1998-10-16 1999-10-12 Therapy for improving cognition

Country Status (20)

Country Link
EP (1) EP1121131A2 (pt)
JP (1) JP2002527469A (pt)
KR (1) KR20010072878A (pt)
CN (1) CN1367697A (pt)
AU (1) AU6472799A (pt)
BG (1) BG105302A (pt)
BR (1) BR9914419A (pt)
CA (1) CA2345767A1 (pt)
EE (1) EE200100136A (pt)
HK (1) HK1039745A1 (pt)
HR (1) HRP20010262A2 (pt)
HU (1) HUP0103781A3 (pt)
ID (1) ID28441A (pt)
IL (1) IL142588A0 (pt)
NO (1) NO20011403D0 (pt)
PL (1) PL348107A1 (pt)
SK (1) SK4592001A3 (pt)
TR (1) TR200101082T2 (pt)
WO (1) WO2000023057A2 (pt)
ZA (1) ZA200103081B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0102841D0 (en) * 2001-02-05 2001-03-21 Novartis Ag Organic compounds
AU2006201188B2 (en) * 2001-02-05 2007-11-15 Novartis Ag New use of iloperidone
EP1441727B1 (en) 2001-10-30 2010-12-29 Novartis AG Depot formulations of iloperidone and a star polymer
GB0216416D0 (en) 2002-07-15 2002-08-21 Novartis Ag Organic compounds
WO2004084905A2 (en) * 2003-03-24 2004-10-07 University Of Florida Use of 5-ht2c receptor activity affecting compounds for treating idiopathic hyperhidrosis and associated conditions
TW200501962A (en) * 2003-04-01 2005-01-16 Novartis Ag Use of carbamazepine derivatives for the treatment of agitation in dementia patients
US20050232990A1 (en) * 2003-12-31 2005-10-20 Garth Boehm Donepezil formulations
JP2008523058A (ja) * 2004-12-10 2008-07-03 アボット・ラボラトリーズ 縮合ビシクロ複素環置換キヌクリジン誘導体
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
WO2008065141A1 (en) 2006-11-30 2008-06-05 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
ZA200905537B (en) 2007-03-01 2010-10-27 Probiodrug Ag New use of glutaminyl cyclase inhibitors
JP5667440B2 (ja) 2007-04-18 2015-02-12 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
MX2007008642A (es) * 2007-07-16 2009-02-25 World Trade Imp Export Wtie Ag Composicion farmaceutica que comprende la combinacion de un agente derivado benzisoxazolico y un agente inhibidor reversible de la enzima colinesterasa, indicada para el control y tratamiento de trastornos psicoticos y demencias.
CA2789014C (en) 2010-02-09 2019-01-15 Michela Gallagher Methods and compositions for improving cognitive function
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
MX2012010470A (es) 2010-03-10 2012-10-09 Probiodrug Ag Inhibidores heterociclicos d ciclasa de glutaminilo (qc, ec .3 2. 5).
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
WO2012123563A1 (en) 2011-03-16 2012-09-20 Probiodrug Ag Benz imidazole derivatives as inhibitors of glutaminyl cyclase
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
CA2904767C (en) 2013-03-15 2022-06-21 Agenebio, Inc. Methods and compositions for improving cognitive function
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
WO2016191288A1 (en) 2015-05-22 2016-12-01 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
EP3461819B1 (en) 2017-09-29 2020-05-27 Probiodrug AG Inhibitors of glutaminyl cyclase

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69229781T2 (de) * 1991-05-14 2000-01-05 Ernir Snorrason Behandlung des ermüdungssyndroms mit cholinesteraseinhibitoren
US5336675A (en) * 1991-05-14 1994-08-09 Ernir Snorrason Method of treating mania in humans
DK1011678T3 (da) * 1997-08-11 2008-05-05 Univ South Florida Anvendelse af mecamylamin til behandling af nikotin-responsive neuropsykiatriske lidelser
ATE369848T1 (de) * 1998-04-14 2007-09-15 Gen Hospital Corp Verwendung von d-serine oder d-alanine zur behandlung von schizophrenie

Also Published As

Publication number Publication date
NO20011403L (no) 2001-03-20
WO2000023057A3 (en) 2000-07-27
HRP20010262A2 (en) 2002-06-30
NO20011403D0 (no) 2001-03-20
CN1367697A (zh) 2002-09-04
EP1121131A2 (en) 2001-08-08
WO2000023057A2 (en) 2000-04-27
SK4592001A3 (en) 2001-12-03
TR200101082T2 (tr) 2001-09-21
PL348107A1 (en) 2002-05-06
KR20010072878A (ko) 2001-07-31
HK1039745A1 (zh) 2002-05-10
ZA200103081B (en) 2002-07-12
ID28441A (id) 2001-05-24
EE200100136A (et) 2002-06-17
BG105302A (en) 2001-11-30
CA2345767A1 (en) 2000-04-27
AU6472799A (en) 2000-05-08
HUP0103781A3 (en) 2003-09-29
HUP0103781A2 (hu) 2002-03-28
BR9914419A (pt) 2001-06-26
JP2002527469A (ja) 2002-08-27

Similar Documents

Publication Publication Date Title
IL142588A0 (en) Therapy for improving cognition
AP2002002661A0 (en) Combination therapy for oesteoporosis
GB9816263D0 (en) Therapeutic agents
GB9806102D0 (en) Therapeutic agents
EP1077704A4 (en) COMBINATION THERAPY FOR TREATING DEPRESSION
GB9804885D0 (en) Therapeutic combination
GB9808663D0 (en) Therapeutic agents
GB9801234D0 (en) Therapeutic agents
GB9813576D0 (en) Therapeutic agents
GB9813006D0 (en) Therapeutic agents
GB9801210D0 (en) Therapeutic agents
GB9816556D0 (en) Therapy
AP9901436A0 (en) Therapeutic agents
GB9801397D0 (en) Therapeutic agents
HUP0101947A3 (en) Combination for the treatment of tumors
GB9801202D0 (en) Therapeutic agents
GB9808665D0 (en) Therapeutic compounds
GB9810092D0 (en) Therapeutic agents
GB9824897D0 (en) Therapeutic compounds
GB9811879D0 (en) Therapeutic agents
GB9815317D0 (en) Therapeutic agents
GB0020261D0 (en) Therapeutic treatment
GB9805716D0 (en) Therapeutic agents
GB9817838D0 (en) Therapeutic agents
GB9808667D0 (en) Therapeutic compounds